Fermi stock price target raised to $33 from $27 at Cantor Fitzgerald

Cantor Fitzgerald has upgraded Madrigal Pharmaceuticals' stock, citing strong sales of its drug Rezdiffra. This positive development reflects confidence in the company's growth and market performance.

Cantor Fitzgerald has reaffirmed its Overweight rating on Xenon Pharmaceuticals stock, signaling strong confidence in the company's future performance. This endorsement is significant as it reflects the firm's belief in Xenon's potential for growth and innovation in the pharmaceutical sector, which could attract more investors and boost the stock's value.

Cantor Fitzgerald has raised its price target for Palantir's stock to $198, driven by the company's promising growth in artificial intelligence. This adjustment reflects confidence in Palantir's potential to capitalize on the booming AI sector, which is crucial for investors looking for opportunities in tech. As AI continues to reshape industries, Palantir's advancements could lead to significant returns, making this news particularly relevant for stakeholders.

Rick Perry's ambitions in the nuclear energy sector are gaining traction, especially with Fermi, a promising startup that has just gone public. This company is well-positioned to capitalize on the growing demand for AI data centers and the potential resurgence of nuclear power. This matters because it highlights a shift towards innovative energy solutions that could play a crucial role in addressing future energy needs.

Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the stability of the sector.

Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the sector's resilience.

Aviat Networks reported a remarkable 21.4% increase in revenue for Q1 FY2026, surpassing market expectations. This growth highlights the company's strong performance and positive outlook in the telecommunications sector.

Stoke Therapeutics recently presented its Q3 2025 results, showcasing impressive revenue growth alongside significant advancements in its clinical programs. The company's progress highlights its commitment to developing innovative therapies, making it a key player in the biotechnology sector.

Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.

Corsair's Q3 2025 slides indicate a strong growth trajectory, despite missing earnings forecasts. The company is navigating challenges while showcasing resilience in its performance.